$SRFM

Surf Air Mobility (NYSE: SRFM) lifts 2026 EBITDA outlook after strong Q1

Surf Air Mobility (NYSE: SRFM) reported strong Q1 2026 results, with revenue of $25.6 million at the high end of guidance and a 9% year-over-year increase, driven by a 77% rise in Surf On Demand private charter revenue. Despite a widened net loss, the Adjusted EBITDA loss improved to $12.3 million, better than expected. Consequently, the company raised its full-year 2026 Adjusted EBITDA loss guidance to a narrower range of $25 million to $30 million, a 40% improvement from its previous outlook, while maintaining revenue guidance.

Original reporting
Published May 11, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 11, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$SRFM
Bullish
medium confidence
Mentioned
$SRFM
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$SRFMBullishMed
01

Why it matters

The positive financial results and outlook revision could boost investor confidence, potentially leading to short-term stock appreciation.

02

Market read

The news is relevant for investors and traders focusing on transportation, mobility, and energy sectors, with immediate implications for SRFM stock.

03

What to watch

Potential regulatory changes or macroeconomic factors could impact the company's performance and stock price.

Timing: Immediate to short-term (next 1-3 months)

Background

Surf Air Mobility's recent quarterly results exceeded revenue guidance, with a notable increase in private charter revenue, leading to an improved EBITDA outlook and guidance revision.

Company-level read

Ticker impact

$SRFMBullishMedium confidence
Context

Primary focus due to recent earnings report and outlook revision.

Expected impact

Moderate upward movement in stock price over the next 1-3 months.

Evidence & confidence

Strong quarterly results and guidance revision indicate positive momentum; however, widened net loss and industry volatility introduce uncertainty.

Market effects

Potential positive impact on the transportation and energy sectors due to increased investor confidence in innovative mobility companies.

Limited regional impact; primarily affects US-based transportation stocks.

Moderate; reflects broader trends in mobility and private transportation sectors.

Counterpoint

The improved EBITDA outlook may be offset by ongoing losses and industry competition, suggesting caution before aggressive positioning.

Key entities

  • Surf Air Mobility

    A mobility service provider focusing on private air travel and related services.

Related articles

$SRFMMed

Why is Surf Air Mobility stock sliding today?

Surf Air Mobility (SRFM) shares fell 2.4% in after-hours to $0.83 after the company released Q2 2026 results and filed an SEC Form 8-K. Analysts expected a Q2 loss of about $0.17 per share versus a $0.26 loss in Q1. The stock also faces an NYSE $1.00 compliance notice from July 24, with a six-month cure period.

$SRFMMed

SURF AIR MOBILITY INC. (SRFM): Results of Operations and Financial Condition

SURF AIR MOBILITY INC. (SRFM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Surf Air Mobility Reports Second Quarter 2026 Financial Results, Meeting Revenue and Adjusted EBITDA Guidance Second Quarter Revenue of $29.5 Million, Driven By Over 100% Year-Over-Year Increase In Surf On Demand Private Charter Revenue, At the High End of the Guidan

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.